Angiogenic GENe Therapy Trial - AGENT-2

Description:

The goal of this trial was to evaluate whether intracoronary administration of the adenoviral gene for fibroblast growth factor (Ad5FGF-4) improves myocardial perfusion compared with placebo in patients with stable angina and reversible ischemia.